$ARWR Macro pressure eased Friday, but biotech still trades on data and cash runway. Key question: can it outperform while yields stay elevated?

$MGY This is a catalyst stock, not a comfort stock. I want to see better evidence in balance-sheet strength and shareholder returns. The upside case is real, but so is the execution risk.

$CTRA has a setup worth watching. Energy volatility keeps this name on the radar. The real test is whether pricing strength converts into free cash flow without sacrificing capital discipline.

$PAA is back on my radar with energy prices elevated. The setup improves if realized pricing stays firm, but I’m still watching free cash flow, leverage and capital discipline before chasing the move.

$SCHW is setting up an interesting technical battle, and the reaction around resistance matters. Higher lows would keep the structure healthy. Losing nearby support would be my signal to reassess.